We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

New Strategies to Treat High Cholesterol

Conrad B. Blum, MD1; Neil J. Stone, MD2
[+] Author Affiliations
1Columbia University College of Physicians and Surgeons, New York, New York
2Feinberg School of Medicine, Northwestern University, Chicago, Illinois
JAMA. 2016;315(11):1169. doi:10.1001/jama.2015.18029.
Text Size: A A A
Published online


To the Editor Dr Shrank and colleagues1 suggested that the advent of proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors may mean reversion to a strategy of striving to achieve low-density lipoprotein cholesterol (LDL-C) goals. They indicated that such a strategy may be needed to avoid substantial drug costs. We disagree.

The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) used an evidence-based approach that resulted in several changes in therapeutic strategy.2 One change was the focus on intensity of treatment rather than achievement of specific LDL-C goals as prior guidelines recommended.3 There were several reasons for this. First, the clinical trials were not designed to select LDL-C goals. Second, strict LDL-C goals can lead to addition of nonstatin drugs when the number needed to treat would be unacceptable in both costs and risks. Third, use of arbitrary goals may lead to undesirable down-titration of therapy in individuals at highest risk. Consider the patient with diabetes and acute coronary syndrome who achieves an LDL-C of 69 mg/dL with a moderate intensity statin. The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) showed benefit from adding ezetimibe.4


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




March 15, 2016
William H. Shrank, MD, MSHS; Jane Barlow, MD
1CVS Health, Woonsocket, Rhode Island
JAMA. 2016;315(11):1169-1170. doi:10.1001/jama.2015.18038.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...